Share Email Print
cover

Proceedings Paper

Laser assisted immunotherapy (LIT) for chemotherapy-resistant neoplasms: recent case reports
Author(s): Robert E. Nordquist; Cody Bahavar; Feifan Zhou; Tomas Hode; Wei R. Chen; Xiaosong Li; Mark F. Naylor
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

T-cell stimulators such as anti-CTLA-4 antibodies enhance immunologic responses to chemotherapy-resistant solid tumors, such as melanoma, advanced breast cancer, ovarian cancer and pancreatic cancer. The efficacy of these new immunotherapy agents can in theory be enhanced substantially by therapies that stimulate new immunologic (T-cell) responses against the tumor. Laser immunotherapy (LIT) with imiquimod and InCVAX are techniques that produce useful responses in patients with advanced melanoma, the prototypical chemotherapy resistant solid tumor. The mechanism of action of these therapies is thought to be immunological, including the development of new T-cell responses. We have therefore been combining LIT using imiquimod and InCVAX treatment with the new T-cell stimulators (ipilimumab) in cases of stage IV melanoma. While still anecdotal, the use of novel combinations of immunologic therapies should provide much improved responses for chemotherapy-resistant solid tumors (such as melanoma) than was previously possible. Newer T-cell stimulating drugs such as the anti-PD-1 antibodies and anti-PD-L1 antibodies will make this general approach to treating chemoresistant advanced tumors even more effective in the future.

Paper Details

Date Published: 27 February 2014
PDF: 7 pages
Proc. SPIE 8944, Biophotonics and Immune Responses IX, 894406 (27 February 2014); doi: 10.1117/12.2041646
Show Author Affiliations
Robert E. Nordquist, Immunophotonics, Inc. (United States)
Cody Bahavar, Univ. of Central Oklahoma (United States)
Feifan Zhou, Univ. of Central Oklahoma (United States)
Tomas Hode, Immunophotonics, Inc. (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)
Xiaosong Li, The First Affiliated Hospital of Chinese PLA General Hospital (China)
Mark F. Naylor, Dermatology Associates of San Antonio (United States)


Published in SPIE Proceedings Vol. 8944:
Biophotonics and Immune Responses IX
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top